Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma

Leuk Res. 2014 Jul;38(7):737-43. doi: 10.1016/j.leukres.2014.03.005. Epub 2014 Mar 18.

Abstract

This is an analysis in 171 patients comparing BEAM-Auto and BEAM-Allo (alemtuzumab)-hematopoietic stem cell transplantation in relapsed follicular lymphoma. BEAM-Allo group had a lower 10 years cumulative incidence of relapse(31.4% vs 55.1%, p=0.042), a trend to a plateau in survival but no statistical differences in OS or DFS, and a TRM of 24%. When transplanted in CR BEAM-Allo patients had better OS and DFS. Incidence of acute and chronic GVHD was 16.6% and 22%. 29% of BEAM-Allo patients received DLI (all but two remain in CR and alive). Our data supports Allo-HSCT as a potential curative treatment for selected patients with FL.

Keywords: Alemtuzumab; BEAM; Follicular lymphoma; Hematopoietic stem cell transplantation.

MeSH terms

  • Adult
  • Aged
  • Alemtuzumab
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Female
  • Follow-Up Studies
  • Graft vs Host Disease / epidemiology
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Lymphocyte Transfusion
  • Lymphoma, Follicular / mortality
  • Lymphoma, Follicular / therapy*
  • Male
  • Middle Aged
  • Recurrence
  • Transplantation, Homologous

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Alemtuzumab